Johnson & Johnson

NYSE:JNJ   3:59:59 PM EDT
143.95
-1.29 (-0.89%)
4:19:00 PM EDT: $143.70 -0.25 (-0.17%)
Earnings Announcements

Sema4 Says Entered Into Research Agreement With Janssen Research & Development Llc To Optimize Oncology Clinical Trials

Published: 09/29/2020 12:36 GMT
Johnson & Johnson (JNJ) - Sema4 - Entered Into Research Agreement With Janssen Research & Development, Llc to Optimize Oncology Clinical Trials.
Sema4 - Will Provide Janssen Access to Co's Industry-leading Genomic Testing and Its Proprietary Centrellis Health Intelligence Platform.
Revenue is expected to be $21.67 Billion
Adjusted EPS is expected to be $1.84

Next Quarter Revenue Guidance is expected to be $21.65 Billion
Next Quarter EPS Guidance is expected to be $2.22

More details on our Analysts Page.